Product information

COSENTYX® is indicated for the treatment of: 

• Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

• Moderate to severe plaque psoriasis in pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.

• Active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX® can be used alone or in combination with methotrexate.

• Active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

• Active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

• Juvenile idiopathic arthritis categories: 

  • Active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.


  • Active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

• Moderate to severe hidradenitis suppurativa (acne inversa) in adult patients who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.

Consult the Product Monograph at www.novartis.ca/CosentyxMonograph for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883.